BCHE Genotype

Succinylcholine is the muscle relaxant anesthesiologists reach for when they need you paralyzed fast. In most people it wears off in about five to ten minutes. If you carry two damaging copies of a gene called BCHE, it can last hours, and you may wake up on a ventilator in recovery with no idea why.

Nothing else about you has to look wrong. You can have no symptoms, a healthy liver, and normal standard labs. The trait is invisible until the day someone gives you the drug. That is the case for knowing your genotype ahead of time.

What the Gene Actually Does

BCHE is on chromosome 3 and codes for an enzyme called butyrylcholinesterase, sometimes called pseudocholinesterase on older lab reports. Your liver makes most of what circulates in your blood. Fat tissue, lungs, colon, and brain support cells make smaller amounts.

The enzyme's job is to chop up certain molecules built around a chemical group called choline. Two surgery drugs, succinylcholine and mivacurium, are built that way. For succinylcholine, most of the dose is broken down in plasma before it reaches the muscle. Slow the enzyme and there is no fast backup route.

The enzyme does other work too. It helps soak up organophosphate pesticides and nerve agents in blood. It can switch off ghrelin, a hunger hormone, by clipping off its fatty tail. It also appears to interact with blood fat-carrying particles. Those jobs do not usually produce symptoms when the enzyme is missing. People born with essentially no working butyrylcholinesterase are generally healthy until a susceptible drug is used.

Prolonged Paralysis After Anesthesia

This is the clinical use with strong human evidence behind it. Two severely damaging copies can leave you with little or no working enzyme, and standard doses of succinylcholine or mivacurium can then produce paralysis that outlasts the surgery.

In one Australian referral cohort after prolonged post-succinylcholine apnea, a five-variant screen found a BCHE abnormality in 80 percent of people. Broader sequencing finds additional rare variants that fixed panels miss.

Two named variants dominate the picture. The atypical or A-variant (p.Asp70Gly, also written p.Asp98Gly) produces an enzyme that cannot grip succinylcholine properly. The K-variant (p.Ala539Thr, also written p.Ala567Thr) mainly affects how much enzyme ends up in your blood. Because these variants often travel together on the same stretch of DNA, many affected people have both the A and K changes.

One K copy by itself is close to a non-event in otherwise healthy surgical patients. In a study of 70 people given succinylcholine, K-variant carriers took at most about four minutes longer to recover than people with two normal copies, and that gap was small next to the ordinary person-to-person spread in recovery times. Two damaging copies is a different situation entirely.

Why the K-Variant Confuses People

For years the K-variant was treated as the explanation for mildly low enzyme activity in the general population. Work tracing which DNA changes travel together on the same copy of the gene has made the story less tidy. The K change by itself appears to leave each enzyme molecule working normally. What drives activity down is the company it keeps: nearby DNA changes that tend to be inherited with it, including one upstream of the gene (rs1126680) and one in a non-coding stretch inside the gene (rs55781031). Those sites affect how much enzyme gets made rather than how well each molecule works.

This matters for reading your own report. Panels that sequence only the protein-coding stretches can call a K-variant and miss the nearby DNA changes that determine whether it means much. A K result with no information about those sites is ambiguous, not automatically mild.

Cholinesterase Inhibitors and Cognitive Decline

Several human cohorts have looked at whether BCHE genotype predicts how people with Alzheimer's disease or mild cognitive impairment respond to cholinesterase inhibitors such as donepezil or rivastigmine. The results conflict. One three-year cohort found K-variant carriers with mild cognitive impairment declined faster on donepezil. A separate analysis pointed the other way on treatment response: carriers of the K allele plus APOE4 declined faster overall but got more cognitive benefit from donepezil. A rivastigmine analysis found sex- and genotype-specific signals rather than a simple K-is-good or K-is-bad rule. A separate cohort of 368 people with dementia found the K allele associated with reduced risk of Alzheimer's disease and Lewy body dementia.

Two large studies add gene-interaction findings. A prospective cohort of 1,696 adults found the combination of APOE4 and the K-variant raised Alzheimer's risk, though it did not predict cognitive decline or brain shrinkage before impairment appeared. A case-control study of 362 people in Northern Ireland found the K allele raised late-onset Alzheimer's risk, more so with age.

The finding changes with the population, the drug, the endpoint, and whether APOE genotype was accounted for. That pattern is consistent with a possible drug-response modifier early in its evidence base, before anyone knows which subgroup it applies to. It is not yet something to base a prescribing decision on, and no guideline body treats it that way.

Metabolic Associations, and What They Are Not

Enzyme activity tracks with metabolic health in large populations. In a cross-sectional study of 844 adults, higher activity went with more liver fat measured on MRI and with worse insulin sensitivity, and the insulin finding held after adjusting for age, sex, body mass index, and liver fat. A study of 2,200 people linked plasma activity to metabolic syndrome. A genome-wide study of 8,791 people found four new DNA regions affecting activity, multiple independent signals within BCHE itself, and secondary links with metabolic risk factors. Twin studies put the heritability of baseline activity somewhere between 65 and 81 percent.

None of that makes this a metabolic test. The strong associations are with the enzyme's measured activity in blood, which is influenced by your genotype but also by body weight, lipids, liver function, and current illness. This test reads the genotype, not the activity. Interpreting a sequencing result as a statement about your insulin sensitivity would be reading the wrong variable.

Pesticide Exposure and Parkinson's Disease

Because the enzyme acts as a sponge for organophosphates, people with less of it may be more exposed at the same external dose. A case-control study of 861 people in Egypt found that K-variant carriers with pesticide exposure had higher Parkinson's disease risk. The variant mattered mainly among exposed people. One occupational study in workers with chronic chemical exposure found lower enzyme activity in exposed groups and a statistical association with rs1803274, but genotype is fixed and that design cannot show exposure changed the gene. This is early interaction evidence in specific populations, not established risk, and it does not by itself justify testing.

Cocaine and Crack

Butyrylcholinesterase is one of the enzymes that breaks down cocaine and is the main cocaine hydrolase in serum. A case-control study of 1,436 people found the AA genotype at rs1803274 was a risk factor for crack cocaine use specifically, the smoked form. Read this as a preliminary difference in how fast the drug clears, not as a genetic explanation for addiction.

A One-Time Result, and What to Track Instead

Your genotype does not change, so this is a once-in-a-lifetime test. There is no trend to follow and no reason to repeat it unless the lab flags low confidence in a variant call, in which case confirming by a second method such as Sanger sequencing is reasonable.

What does need following up is different. If you carry a clinically significant variant, the useful companion measurement is your actual plasma butyrylcholinesterase activity, because activity moves with liver disease, pregnancy, burns, severe illness, and organophosphate exposure. Someone with one damaging copy and healthy liver function may clear succinylcholine adequately; the same person with cirrhosis or during a severe illness may not. The genotype tells you your inherited starting point. Activity tells you where you stand today.

The other thing to carry forward is the record itself. A variant in a file you cannot find at 6 a.m. on the day of surgery is no protection. Put it somewhere you and your family can produce it: a medical alert card, your phone's emergency health record, your chart.

What to Do With an Abnormal Result

The action depends on what the report actually says. Two loss-of-function copies, or two different damaging variants with one on each copy of the gene, is the pattern that matters most. Tell every anesthesiologist and surgeon before any procedure, including dental surgery and endoscopy. Succinylcholine and mivacurium can be swapped for alternatives that do not depend on this enzyme, so the finding changes the anesthetic plan rather than ruling out surgery.

One K-variant copy with no other findings is the common and less consequential result. Note it, mention it to an anesthesiologist, and do not expect it to change anything on its own.

Two other pathways matter. First, if you get a variant call and your measured enzyme activity does not line up with it, that combination is the signal to bring in a medical geneticist or an anesthesiologist who handles perioperative pharmacogenetics, because discordance is common and resolving it takes both numbers. Second, this trait is usually inherited in a recessive pattern. It usually takes two affected copies to cause the problem. If you carry two, each full sibling has a meaningful chance of carrying one or two. Each child will inherit one affected copy from you and could have two if the other biological parent carries a BCHE variant. Testing relatives before their surgeries is the most useful thing a positive result buys, and it is the main reason to test if the prolonged-paralysis episode in your family happened to someone other than you.

What This Test Cannot Tell You

Sequencing detects the variants and regions the assay is built to read. A negative result does not rule out a rare change elsewhere in the gene, and panels limited to the handful of best-known mutations miss roughly 15 to 20 percent of clinically meaningful variants. Coding-only panels systematically miss the nearby non-coding sites that determine whether a K-variant matters.

Insertions and small structural changes are harder to call than single-letter substitutions. A published case describes an insertion in BCHE that the DNA-copying method used to read the gene missed entirely in a person who had the deficiency. Rare or novel calls are often confirmed by a second method before they are used for anesthesia planning.

Which variants are common depends on ancestry, and most of the sequencing work has been done in European, Japanese, Brazilian, and Australian cohorts. If your ancestry is poorly represented in the reference data, the chance of a finding with uncertain meaning goes up. This test reads the DNA you inherited, so a sample carrying tumor DNA or donor DNA after a bone marrow transplant can confuse the call. Tell the lab if the sample source is unusual.

A raw-data flag from a direct-to-consumer DNA array is a clue, not a surgical record. Consumer arrays usually check selected sites. They can miss rare BCHE changes, miss nearby non-coding sites, or miscall a variant. A result that will change an anesthesia plan should come from a clinical lab.

A normal result on a routine blood panel says nothing about this. Your comprehensive metabolic panel does not include cholinesterase activity, and even total cholinesterase activity can look normal in someone carrying variants. In a systematic review of 290 people, 72 percent of those classified as biochemically normal carried at least one BCHE variant. That does not mean all were at high anesthetic risk. It means enzyme activity and genotype are not the same answer.